New registry open : RELIVE

The international sponsor of the RELIVE registry is the Geneva University Hospital. In Belgium, the registry is coordinated by the Cliniques Universitaires Saint Luc, with Pr. Dr. Bénédicte Brichard acting as national coordinating investigator.

This registry is open in Belgium thanks to the financial support of Kinderkankerfonds.

Newly diagnosed hepatoblastoma (HB), hepatocellular carcinoma (HCC) or  hepatocellular neoplasm not otherwise specified (HCN-NOS) patients are usually treated within the framework of a clinical trial with well-defined treatment options which vary according to the extent of disease and anticipated prognosis of the individual case.  Some patients will not be cured with upfront therapy and are considered to have treatment-refractory disease. Other patients may relapse after having been in remission. Patients with refractory or relapsed disease traditionally receive additional treatment which may include chemotherapy or additional surgical and/or interventional approaches aimed towards achieving local control.  This “salvage” treatment is usually not specified in upfront trial protocols and is therefore largely individualized according to single institution opinion.

Long term outcome for patients with refractory or relapsed HB, HCC, and HCN-NOS is unsatisfactory. The international consortium currently conducting the another trial about hepatic pediatric cancer plans to incorporate treatment guidelines and data acquisition for relapsed and refractory patients in a prospective fashion as part of a future protocol. The objective of RELIVE protocol is to collect data regarding currently utilized treatment regimens as well as short and long term patient outcome to guide writing of this future proposal. The retrospective collection of cases in a central registry will allow for a systematic overview and statistical assessment of the various approaches used.

Learn more